GenomOncology announces participation in Biden Cancer Initiative’s OCTIC
GenomOncology is excited to be a part of the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC), joining forces with 8 other organizations to improve clinical trial matching and enrollment for patients.
GenomOncology is excited to be a part of the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC), joining forces with 8 other organizations to improve clinical trial matching and enrollment for patients. The Biden Cancer Initiative recently announced the Oncology Clinical Information Commons, a new shared infrastructure that will make it possible for cancer patients to know their clinical trial options. GenomOncology joins 8 other organizations to help in these efforts and make matching technology and services more accessible for patients, clinicians, and others.
Finding potential treatment options among the thousands of clinical trials with complicated eligibility criteria can be difficult and GenomOncology is striving to make the process easier and more automated. We are dedicated to providing software-based solutions for precision oncology that measurably impact patient treatment options, focused on clinical trials, therapies, and more. We believe that real-time decision support for oncologists at the point-of-care will accelerate clinical trial enrollment and improve patient outcomes.
Our Clinical Trial Matching solutions allow clinicians to match patients to potential treatments and clinical trials based on the combination of variant interpretations and disease information. GenomOncology supports the Biden Cancer Initiative’s to make a new shared infrastructure that goes beyond simply searching by a patient’s diagnosis, but dives into genomic and molecular results for better trial matching for patients.
Learn more about the Biden Cancer Initiative’s announcement by visiting their medium article .
Learn more about GenomOncology and our mission to accelerate personalized medicine and improve patient outcomes through real-time decision support, by visiting our website at genomoncology.com or our medium post .